Re: MRK and FoB’s
>why wait?<
Why, indeed. I don’t question MRK’s decision-making at all; rather, I question the way the program has been framed for investors.
MRK is evidently using the definition that any drug with the same amino-acid sequence as an approved drug is an FoB. If other companies (e.g. AZN) start using this definition, as they probably will, we’ll have to come up with a new term to connote a biologic that is approved by relying in part on the clinical data for a reference drug. “Biosimilar” doesn’t do the trick because many people consider it a synonym for FoB.
My last post on this particular matter for the time being.
Market Data 
Markets 
AI
